Janux Therapeutics (JANX) Other Non-Current Assets (2021 - 2026)

Janux Therapeutics (JANX) has reported Other Non-Current Assets for 6 consecutive years, with $3.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Assets rose 41.26% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (up 41.26% YoY), while the FY2025 annual figure was $816000.0, changed 0.0% from the prior year.
• Other Non-Current Assets advanced to $3.9 million in Q1 2026 per JANX's latest filing, from $816000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $3.9 million in Q1 2026 and bottomed at $816000.0 in Q1 2022.
• Historically, Other Non-Current Assets has averaged $1.6 million across 5 years, with a median of $816000.0 in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets soared 482.86% — and 2024, when it plunged 67.48%.
• Janux Therapeutics' Other Non-Current Assets stood at $816000.0 in 2022, then surged by 207.48% to $2.5 million in 2023, then slumped by 67.48% to $816000.0 in 2024, then changed by 0.0% to $816000.0 in 2025, then jumped by 383.33% to $3.9 million in 2026.
• Business Quant data shows JANX's Other Non-Current Assets at $3.9 million in Q1 2026, $816000.0 in Q4 2025, and $816000.0 in Q3 2025.